Table 2. Results of pooled analysis for TP73 G4C14-A4T14 polymorphism and cancer susceptibility.
| Comparison | Subgroup | N | PH | PZ | Random | Fixed |
|---|---|---|---|---|---|---|
| B vs. A | Overall | 36 | <0.001 | 0.002* | 1.139 (1.048–1.238) | 1.170 (1.119–1.223) |
| Caucasian | 14 | 0.001 | <0.001* | 1.279 (1.131–1.446) | 1.317 (1.232–1.407) | |
| Asian | 22 | <0.001 | 0.228 | 1.062 (0.963–1.172) | 1.060 (0.998–1.126) | |
| Breast cancer | 3 | 0.091 | 0.940 | 0.985 (0.666–1.457) | 0.929 (0.747–1.156) | |
| Colorectal cancer | 4 | 0.339 | 0.011* | 1.197 (1.027–1.395) | 1.204 (1.044–1.389) | |
| SCCHN | 3 | 0.007 | 0.062 | 1.308 (0.987–1.733) | 1.274 (1.134–1.432) | |
| Cervical cancer | 6 | 0.982 | 0.031* | 1.190 (1.016–1.393) | 1.189 (1.016–1.392) | |
| Esophageal cancer | 4 | 0.010 | 0.873 | 1.027 (0.738–-1.430) | 1.057 (0.903–1.236) | |
| Gastric cancer | 4 | 0.739 | 0.261 | 1.084 (0.943–1.247) | 1.084 (0.942–1.247) | |
| Lung cancer | 5 | <0.001 | 0.657 | 0.943 (0.726–1.224) | 1.034 (0.945–1.132) | |
| P-B | 20 | <0.001 | 0.176 | 1.082 (0.965–1.213) | 1.098 (1.033–1.168) | |
| H-B | 16 | <0.001 | 0.001* | 1.213 (1.079–1.365) | 1.256 (1.177–1.340) | |
| HWE(Y) | 32 | <0.001 | 0.003* | 1.138 (1.044–1.239) | 1.165 (1.109–1.222) | |
| HWE(N) | 4 | <0.001 | 0.484 | 1.132 (0.799–1.604) | 1.200 (1.071–1.345) | |
| BB vs. AA | Overall | 36 | <0.001 | 0.009* | 1.320 (1.071–1.627) | 1.420 (1.265–1.593) |
| Caucasian | 14 | <0.001 | 0.011* | 1.649 (1.119–2.431) | 1.806 (1.523–2.142) | |
| Asian | 22 | 0.033 | 0.151 | 1.170 (0.944–1.450) | 1.152 (0.984–1.350) | |
| Breast cancer | 3 | 0.189 | 0.952 | 0.918 (0.370–2.279) | 0.983 (0.558–1.732) | |
| Colorectal cancer | 4 | 0.676 | 0.001* | 1.807 (1.258–2.595) | 1.820 (1.270–2.608) | |
| SCCHN | 3 | 0.136 | 0.196 | 1.336 (0.807–2.211) | 1.235 (0.897–1.699) | |
| Cervical cancer | 6 | 0.949 | 0.697 | 0.925 (0.590–1.451) | 0.916 (0.587–1.428) | |
| Esophageal cancer | 4 | 0.048 | 0.734 | 1.165 (0.484–2.804) | 1.168 (0.762–1.79) | |
| Gastric cancer | 4 | 0.815 | 0.114 | 1.351 (0.935–1.951) | 1.345 (0.931–1.944) | |
| Lung cancer | 5 | 0.001 | 0.748 | 0.912 (0.522–1.595) | 1.039 (0.823–1.311) | |
| P-B | 20 | 0.002 | 0.470 | 1.107 (0.841–1.457) | 1.136 (0.968–1.335) | |
| H-B | 16 | 0.001 | 0.001* | 1.625 (1.210–2.183) | 1.809 (1.532–2.136) | |
| HWE(Y) | 32 | <0.001 | 0.007* | 1.342 (1.085–1.659) | 1.476 (1.303–1.671) | |
| HWE(N) | 4 | 0.001 | 0.579 | 1.288 (0.526–3.152) | 1.117 (0.819–1.524) | |
| BA vs. AA | Overall | 36 | <0.001 | 0.028* | 1.123 (1.012–1.245) | 1.133 (1.070–1.200) |
| Caucasian | 14 | <0.001 | 0.008* | 1.252 (1.061–1.477) | 1.251 (1.149–1.362) | |
| Asian | 22 | <0.001 | 0.458 | 1.049 (0.924–1.191) | 1.044 (0.966–1.129) | |
| Breast cancer | 3 | 0.100 | 0.284 | 0.941 (0.587–1.510) | 0.859 (0.651–1.134) | |
| Colorectal cancer | 4 | 0.026 | 0.901 | 0.978 (0.693–1.381) | 1.059 (0.879–1.276) | |
| SCCHN | 3 | 0.002 | 0.051 | 1.494 (0.998–2.236) | 1.446 (1.246–1.678) | |
| Cervical cancer | 6 | 0.748 | 0.001* | 1.414 (1.159–1.725) | 1.413 (1.159–1.722) | |
| Esophageal cancer | 4 | 0.031 | 0.953 | 1.011 (0.702–1.457) | 1.023 (0.841–1.244) | |
| Gastric cancer | 4 | 0.295 | 0.867 | 1.007 (0.821–1.234) | 1.015 (0.849–1.214) | |
| Lung cancer | 5 | 0.002 | 0.781 | 0.964 (0.742–1.251) | 1.044 (0.929–1.172) | |
| P-B | 20 | <0.001 | 0.129 | 1.113 (0.969–1.279) | 1.118 (1.033–1.209) | |
| H-B | 16 | <0.001 | 0.129 | 1.134 (0.964–1.334) | 1.152 (1.059–1.253) | |
| HWE(Y) | 32 | <0.001 | 0.065 | 1.101 (0.994–1.219) | 1.098 (1.032–1.169) | |
| HWE(N) | 4 | <0.001 | 0.325 | 1.245 (0.805–1.927) | 1.348 (1.165–1.560) | |
| BB+BA vs. AA | Overall | 36 | <0.001 | 0.005* | 1.152 (1.044–1.272) | 1.174 (1.111–1.240) |
| Caucasian | 14 | 0.004 | <0.001* | 1.312 (1.140–1.511) | 1.327 (1.224–1.440) | |
| Asian | 22 | <0.001 | 0.332 | 1.063 (0.940–1.203) | 1.059 (0.984–1.141) | |
| Breast cancer | 3 | 0.096 | 0.860 | 0.959 (0.605–1.520) | 0.880 (0.675–1.148) | |
| Colorectal cancer | 4 | 0.073 | 0.538 | 1.092 (0.824–1.447) | 1.151 (0.964–1.375) | |
| SCCHN | 3 | 0.001 | 0.061 | 1.482 (0.982–2.237) | 1.415 (1.226–1.633) | |
| Cervical cancer | 6 | 0.861 | 0.003* | 1.339 (1.107–1.619) | 1.338 (1.106–1.618) | |
| Esophageal cancer | 4 | 0.020 | 0.910 | 1.022 (0.706–1.477) | 1.050 (0.870–1.267) | |
| Gastric cancer | 4 | 0.477 | 0.522 | 1.058 (0.892–1.255) | 1.057 (0.892–1.254) | |
| Lung cancer | 5 | <0.001 | 0.694 | 0.943 (0.704–1.263) | 1.045 (0.935–1.167) | |
| P-B | 20 | <0.001 | 0.130 | 1.112 (0.969–1.275) | 1.124 (1.043–1.211) | |
| H-B | 16 | <0.001 | 0.012* | 1.204 (1.042–1.392) | 1.234 (1.139–1.337) | |
| HWE(Y) | 32 | <0.001 | 0.010* | 1.138 (1.032–1.255) | 1.150 (1.084–1.221) | |
| HWE(N) | 4 | <0.001 | 0.376 | 1.223 (0.783–1.911) | 1.315 (1.143–1.512) | |
| BB vs. BA+AA | Overall | 36 | <0.001 | 0.021* | 1.273 (1.038–1.563) | 1.374 (1.227–1.538) |
| Caucasian | 14 | <0.001 | 0.046* | 1.509 (1.008–2.261) | 1.697 (1.437–2.005) | |
| Asian | 22 | 0.074 | 0.097 | 1.160 (0.951–1.415) | 1.141 (0.976–1.332) | |
| Breast cancer | 3 | 0.172 | 0.798 | 0.984 (0.388–2.493) | 1.075 (0.617–1.875) | |
| Colorectal cancer | 4 | 0.512 | 0.002* | 1.746 (1.228–2.484) | 1.760 (1.241–2.496) | |
| SCCHN | 3 | 0.416 | 0.642 | 1.075 (0.782–1.477) | 1.078 (0.786–1.477) | |
| Cervical cancer | 6 | 0.913 | 0.349 | 0.825 (0.530–1.286) | 0.811 (0.524–1.256) | |
| Esophageal cancer | 4 | 0.052 | 0.688 | 1.193 (0.504–2.824) | 1.165 (0.764–1.777) | |
| Gastric cancer | 4 | 0.717 | 0.118 | 1.342 (0.934–1.927) | 1.334 (0.929–1.915) | |
| Lung cancer | 5 | 0.006 | 0.794 | 0.938 (0.578–1.521) | 1.029 (0.818–1.294) | |
| P-B | 20 | 0.006 | 0.532 | 1.086 (0.839–1.404) | 1.106 (0.945–1.296) | |
| H-B | 16 | <0.001 | 0.005* | 1.545 (1.139–2.094) | 1.734 (1.474–2.039) | |
| HWE(Y) | 32 | <0.001 | 0.011* | 1.309 (1.063–1.613) | 1.446 (1.280–1.633) | |
| HWE(N) | 4 | 0.003 | 0.743 | 1.145 (0.509–2.579) | 1.000 (0.736–1.358) |
PH: P value of Q-test for heterogeneity test; PZ: means statistically significant (P<0.05); HWE, Hardy–Weinberg equilibrium; N, polymorphisms did not conform to HWE in the control group; P-B, population based; SCCHN, squamous cell carcinoma of the head and neck; Y, polymorphisms conformed to HWE in the control group; *P value less than 0.05 was considered as statistically significant.